Research
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
-
* Corresponding author: Feng Xie fengxie@mcmaster.ca
Cost Effectiveness and Resource Allocation 2009, 7:20 doi:10.1186/1478-7547-7-20
No comments have yet been made on this article.